Sign In
Buy HIMS
$28.01
+0.500 (+1.82%)
At Close: Jun 04, 2026
Hims & Hers Health, Inc. (HIMS) Q2 2025 Earnings Call Transcript
10:05pm, Monday, 04'th Aug 2025
Hims & Hers Health, Inc. (NYSE:HIMS ) Q2 2025 Earnings Conference Call August 4, 2025 5:00 PM ET Company Participants Andrew Dudum - Co-Founder, Chairman & CEO Bill Newby - Head of Investor Relations
Hims & Hers (HIMS) Q2 Revenue Jumps 73%
07:35pm, Monday, 04'th Aug 2025
Hims & Hers Health (HIMS 1.38%), a direct-to-consumer digital health platform focusing on telehealth, subscription medications, and personalized care, released its second quarter 2025 results on Augus
Hims & Hers Health, Inc. (HIMS) Misses Q2 Earnings and Revenue Estimates
06:47pm, Monday, 04'th Aug 2025
Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.06 per share a year ago.
Hims & Hers sees ‘an exciting period of growth,' but stock falls
05:15pm, Monday, 04'th Aug 2025
Shares of Hims & Hers Inc. fell after hours on Monday after the wellness and telehealth platform's third-quarter forecast came up shy of Wall Street's estimates, although the company stuck with its fu
Hims & Hers stock falls 10% on revenue miss
04:53pm, Monday, 04'th Aug 2025
Hims & Hers Health shares fell in extended trading after the company reported second-quarter results that missed Wall Street's expectations for revenue. Revenue increased 73% year over year to $544.8
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS).
EARNINGS ALERT: PLTR, HIMS
04:30pm, Monday, 04'th Aug 2025
Palantir (PLTR) topped Street expectations for its top and bottom line figures in its latest quarterly report. But, as Kevin Green and Alex Coffey point out: The company's guidance raise was the more
Hims and Hers beats quarterly profit on steady subscription growth
04:19pm, Monday, 04'th Aug 2025
Hims and Hers Health beat Wall Street estimates for second-quarter profit on Monday, aided by continued subscription growth and surging volume in the telehealth company's weight-loss business.
Hims & Hers Health, Inc. Reports Second Quarter 2025 Financial Results
04:05pm, Monday, 04'th Aug 2025
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the secon
SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- This latest development follows an announcement by Novo Nordisk on June 23, 2025, the Danish maker of the FDA-approved weight-loss medication Wegovy®
NEW YORK , Aug. 4, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS). Shareholders who purchased shares of HIMS during the c
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) inv
2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run
03:29pm, Sunday, 03'rd Aug 2025
It's been a wild first half of the year for stocks in 2025, but finding the right companies for your portfolio is a very personal process. You need to consider the type of stocks you want to buy, the
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit
01:29pm, Sunday, 03'rd Aug 2025
NEW YORK , Aug. 3, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and J
SAN DIEGO, Aug. 03, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 2
